Application of Gypensapogenin A in medicine for treating rheumatoid arthritis

An arthritis and rheumatoid technology, applied in the application field of Gypensapogenin A in the treatment of rheumatoid arthritis drugs, can solve problems such as ulcers, poor action selectivity, and damage to the gastrointestinal mucosa

Active Publication Date: 2013-12-18
如东文园投资开发有限公司
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, for rheumatoid arthritis, non-steroidal anti-inflammatory drugs (diclofenac, aspirin, etc.) and immunosuppressants (6-mercaptopurine, etc.) Gastrointestinal mucosa leads to peptic ulcer, which has poor selectivity and is easy to induce infection, etc.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of Gypensapogenin A in medicine for treating rheumatoid arthritis
  • Application of Gypensapogenin A in medicine for treating rheumatoid arthritis
  • Application of Gypensapogenin A in medicine for treating rheumatoid arthritis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0011] Example 1: Preparation of Gypensapogenin A tablets of the compound involved in the present invention:

[0012] Take 20 grams of compound Gypensapogenin A, add 180 grams of conventional excipients for preparing tablets, mix them, and prepare 1,000 tablets with a conventional tablet press.

Embodiment 2

[0013] Example 2: Preparation of the compound Gypensapogenin A capsule of the present invention:

[0014] Take 20 grams of the compound Gypensapogenin A, add it to the conventional auxiliary materials for preparing capsules, such as 180 grams of starch, mix well, and encapsulate to make 1000 tablets.

[0015] The following pharmacodynamic experiments will further illustrate its drug activity.

experiment example 1

[0016] Experimental example 1. The effect of Gypensapogenin A of the present invention on adjuvant arthritis in rats

[0017] Difco was ground and mixed with liquid paraffin to make 10mg / ml. After autoclaving, it was made into Freund's complete adjuvant. Male SD rats were injected intracutaneously with 50 ul of the above adjuvant into the right hind paw, and 50 ul was injected intracutaneously at the tail about 3 cm from the base of the tail. The volume of the left and right foot of the rat was measured before and after the injection, respectively. The difference between represents the degree of swelling. Since the 16th day after the adjuvant injection, the left hind foot of the rats was significantly swollen. The rats were divided into groups according to the degree of swelling and body weight. The experimental group was given Gypensapogenin A 5.0, 10.0, 20.0 mg / kg orally, and the positive control group was given diclofenac orally 10mg / kg, the control group was given an equal v...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides Gypensapogenin A for treating immune inflammation and application of Gypensapogenin A in a medicine for treating rheumatoid arthritis. Compared with terfenadine and diclofenac sodium, Gypensapogenin A has accurate curative effects. The application of Gypensapogenin B in preparing the medicine for treating rheumatoid arthritis, which is provided by the invention, is disclosed for the first time. The skeleton type belongs to brand-new skeleton type, and the rheumatoid arthritis inhibiting activity of Gypensapogenin A is extremely strong, so that no possibility for providing any prompt by other compounds exists. Gypensapogenin A has outstanding actual characteristics. Meanwhile, Gypensapogenin A has outstanding progress when being used for preventing and treating rheumatoid arthritis.

Description

Technical field [0001] The invention relates to the application of Gypensapogenin A in the preparation of drugs for treating rheumatoid arthritis. Background technique [0002] Rheumatoid arthritis is a common clinical disease and frequently-occurring disease. Rheumatoid arthritis is an autoimmune disease and belongs to the category of immune inflammation. At present, for rheumatoid arthritis, non-steroidal anti-inflammatory drugs (diclofenac, aspirin, etc.) and immunosuppressants (6-mercaptopurine, etc.) are mainly used for treatment, but these drugs have obvious adverse reactions, such as the former injury The mucosa of the gastrointestinal tract causes peptic ulcer, which has poor selectivity and is easy to induce infection. Therefore, compounds with clear ingredients, controllable quality, and safe and efficient have potential value in the development of rheumatoid arthritis treatment drugs. [0003] The compound Gypensapogenin A involved in the present invention was publishe...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/58A61P29/00A61P19/02
Inventor 李丽丽施桦吴俊华
Owner 如东文园投资开发有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap